FY2019 Earnings Estimate for FibroGen, Inc (FGEN) Issued By William Blair
FibroGen, Inc (NASDAQ:FGEN) – William Blair reduced their FY2019 earnings per share estimates for shares of FibroGen in a note issued to investors on Wednesday. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn $1.41 per share for the year, down from their prior estimate of $5.29. William Blair has a “Outperform” rating on the stock.
A number of other brokerages have also issued reports on FGEN. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price on the stock. in a research report on Friday, July 21st. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Jefferies Group LLC assumed coverage on shares of FibroGen in a research report on Monday, July 10th. They set a “buy” rating and a $50.00 target price on the stock. Citigroup Inc. reiterated a “buy” rating and set a $48.00 target price on shares of FibroGen in a research report on Monday, June 26th. Finally, Stifel Nicolaus upped their target price on shares of FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $60.17.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/fy2019-earnings-estimate-for-fibrogen-inc-fgen-issued-by-william-blair.html.
FibroGen (NASDAQ FGEN) opened at 52.40 on Friday. The company’s market cap is $3.73 billion. FibroGen has a one year low of $15.60 and a one year high of $52.70. The firm has a 50-day moving average of $43.31 and a 200-day moving average of $32.07.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million.
In other news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $33.38, for a total transaction of $1,289,669.68. Following the transaction, the chief executive officer now directly owns 3,330,780 shares in the company, valued at $111,181,436.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Pat Cotroneo sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $30.00, for a total transaction of $165,000.00. Following the transaction, the vice president now owns 168,866 shares in the company, valued at $5,065,980. The disclosure for this sale can be found here. Insiders have sold 509,328 shares of company stock worth $21,719,918 over the last quarter. 14.90% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its stake in shares of FibroGen by 0.4% during the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of FibroGen by 1.4% during the first quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock worth $11,546,000 after buying an additional 6,512 shares during the last quarter. Sphera Funds Management LTD. raised its stake in shares of FibroGen by 6.4% during the first quarter. Sphera Funds Management LTD. now owns 165,700 shares of the biopharmaceutical company’s stock worth $4,085,000 after buying an additional 10,000 shares during the last quarter. Parametric Portfolio Associates LLC bought a new stake in shares of FibroGen during the first quarter worth approximately $249,000. Finally, BlackRock Inc. raised its stake in shares of FibroGen by 29,724.1% during the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the last quarter. 47.49% of the stock is owned by institutional investors and hedge funds.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.